{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:02:47Z","timestamp":1789732967029,"version":"4.0.1"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"am","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The therapeutic landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has changed significantly over the last decade with the introduction of combination strategies. However, recent real-world evidence on their use in practice is limited, especially in Europe and Asia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included men with mHSPC receiving first-line therapy in EU4, the UK, Japan and China between January 1, 2020, and December 31, 2024. The IQVIA Oncology Dynamics database was used to derive patient-level data on physician-reported initial treatment for mHSPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 23,101 men included, 15,275, 4,875, and 2,951 in EU4, the UK, and Asia, received treatment for mHSPC. Use of androgen deprivation therapy (ADT) monotherapy ranged from 29\u201344% in EU4\/UK and 50\u201359% in Asia. ADT plus androgen receptor inhibitor (ARPI) was used in 47% of patients in EU4, 54% in the UK, and 35\u201338% in Asia. From 2020\u20132024, ADT monotherapy decreased from 60% to 24% in EU4, 54% to 23% in the UK, and 83% to 39% in Asia, with corresponding increases in ADT plus ARPI use. ADT plus ARPI plus docetaxel use increased throughout the study, becoming more prominent from 2023 in EU4\/UK; usage went from 0.1% in 2020 to 10% in 2024. Uptake was slower in Asia. Compared with recurrent mHSPC, a high proportion received combination therapy for de novo mHSPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Findings highlight the adoption of combination strategies with either doublet or docetaxel triplet regimens between 2020 and 2024. One-fourth of patients received ADT monotherapy in 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag369","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:25:18Z","timestamp":1789673118000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns in men with metastatic hormone-sensitive prostate cancer in Europe and Asia between 2020 and 2024"],"prefix":"10.1093","author":[{"given":"Amit D","family":"Raval","sequence":"first","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals , Whippany, NJ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Mpima","sequence":"additional","affiliation":[{"name":"IQVIA , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Casey","sequence":"additional","affiliation":[{"name":"IQVIA , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fil","family":"Manuguid","sequence":"additional","affiliation":[{"name":"IQVIA , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Korn","sequence":"additional","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals , Whippany, NJ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[{"name":"Hospital Universitario Medical Oncology, 12 de Octubre, Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,17]]},"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag369\/71224298\/oyag369.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag369\/71224298\/oyag369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:19:31Z","timestamp":1789730371000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article\/doi\/10.1093\/oncolo\/oyag369\/8817096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag369","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"oyag369"}}